JP2023531679A - 血友病を処置するための方法および組成物 - Google Patents

血友病を処置するための方法および組成物 Download PDF

Info

Publication number
JP2023531679A
JP2023531679A JP2022578970A JP2022578970A JP2023531679A JP 2023531679 A JP2023531679 A JP 2023531679A JP 2022578970 A JP2022578970 A JP 2022578970A JP 2022578970 A JP2022578970 A JP 2022578970A JP 2023531679 A JP2023531679 A JP 2023531679A
Authority
JP
Japan
Prior art keywords
patient
phytusilane
hemophilia
inhibitor
qol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022578970A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531679A5 (https=
Inventor
バイソン・メイ
ショーナ・アンデション
キフェン・ユー
プロナベッシュ・ダズマハパトラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of JP2023531679A publication Critical patent/JP2023531679A/ja
Publication of JP2023531679A5 publication Critical patent/JP2023531679A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2022578970A 2020-06-22 2021-06-22 血友病を処置するための方法および組成物 Pending JP2023531679A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063042390P 2020-06-22 2020-06-22
US63/042,390 2020-06-22
PCT/US2021/038445 WO2021262695A1 (en) 2020-06-22 2021-06-22 Methods and compositions for treating hemophilia

Publications (2)

Publication Number Publication Date
JP2023531679A true JP2023531679A (ja) 2023-07-25
JP2023531679A5 JP2023531679A5 (https=) 2024-07-02

Family

ID=76943130

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022578970A Pending JP2023531679A (ja) 2020-06-22 2021-06-22 血友病を処置するための方法および組成物

Country Status (12)

Country Link
US (2) US20210393669A1 (https=)
EP (1) EP4168018A1 (https=)
JP (1) JP2023531679A (https=)
KR (1) KR20230027277A (https=)
CN (1) CN115942940A (https=)
AU (1) AU2021296786A1 (https=)
BR (1) BR112022026265A2 (https=)
CA (1) CA3188137A1 (https=)
IL (1) IL299295A (https=)
MX (1) MX2023000164A (https=)
TW (1) TW202216172A (https=)
WO (1) WO2021262695A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240075001A1 (en) * 2022-05-24 2024-03-07 Darren Rubin Methods to reduce hemorrhage and mortality on the battlefield and applications for trauma patients
US20240000744A1 (en) * 2022-06-08 2024-01-04 Genzyme Corporation Treatment of Hemophilia with Fitusiran
CN118460655B (zh) * 2024-07-10 2025-01-28 凯莱英医药集团（天津）股份有限公司 抑制FXI基因表达的siRNA的制备方法
WO2026012399A1 (zh) * 2024-07-10 2026-01-15 正大天晴药业集团股份有限公司 靶向serpinc1的双链核糖核酸

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
KR20180095843A (ko) 2015-12-07 2018-08-28 젠자임 코포레이션 Serpinc1-연관 장애의 치료를 위한 방법 및 조성물
TW202434265A (zh) * 2017-07-10 2024-09-01 美商健贊公司 於患有血友病之個體中治療出血事件之方法及組成物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. Vol.128, No.22, Article No.1397, JPN6026003447, 2016, ISSN: 0005787251 *
BLOOD, vol. vol.134, supplement 1, no.1138, JPN6025031009, 2019, ISSN: 0005787255 *
FRONTIERS IN HAEMOPHILIA, vol. 2, no. 1, JPN6026003446, 2015, pages 19 - 22, ISSN: 0005787253 *
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 377, no. 9, JPN6025031008, 2017, pages 819 - 828, ISSN: 0005787252 *
梶原真清恵、嶋緑倫、吉岡章: "2) 出血を予防することにより歩行可能となった２例", 日本血栓止血学会誌, vol. 19, no. 4, JPN6026003445, 2008, pages 548, ISSN: 0005787254 *

Also Published As

Publication number Publication date
WO2021262695A1 (en) 2021-12-30
KR20230027277A (ko) 2023-02-27
BR112022026265A2 (pt) 2023-01-17
MX2023000164A (es) 2023-07-06
TW202216172A (zh) 2022-05-01
AU2021296786A1 (en) 2023-02-23
CN115942940A (zh) 2023-04-07
IL299295A (en) 2023-02-01
CA3188137A1 (en) 2021-12-30
US20260014188A1 (en) 2026-01-15
US20210393669A1 (en) 2021-12-23
EP4168018A1 (en) 2023-04-26

Similar Documents

Publication Publication Date Title
JP2023531679A (ja) 血友病を処置するための方法および組成物
KR20230117403A (ko) 피투시란을 이용한 혈우병의 치료
US20240417739A1 (en) Compositions and methods for treatment of bleeding disorders
WO2022120291A1 (en) Treatment of hemophilia with fitusiran
KR20250024800A (ko) A형 및 b형 혈우병의 치료를 위한 피투시란
US20250064842A1 (en) Fitusiran for Use in Improving Patient-Reported Outcome in Hemophilia Patients
TW202417014A (zh) 於小兒患者中以非妥西蘭治療血友病
CN116635040A (zh) 用非妥西兰治疗血友病
CN116723863A (zh) 用于治疗出血性病症的组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203